Impact Therapeutics Inc., of Shanghai, said the CFDA granted approval for an IND application for phase I testing of IMP-4297, a PARP inhibitor. The company dosed the first patient in an Australian phase I trial and has since initiated phase I testing in China.
Read More
PERTH, Australia – The TGA is seeking industry comments on its proposal to beef up sanctions and penalties as part of its overhaul of drug and device regulations.
Read More
HONG KONG – Novartis AG's South Korean branch faces a double whammy of hefty fines and suspension of state insurance reimbursement on its products.
Read More
DUBLIN – Shares in Poxel SA opened Thursday at €10.22 (US$11.21) on the Euronext exchange in Paris, up 56 percent on the previous close, in response to positive top-line data from a phase IIb trial in Japan of imeglimin in 299 patients with type 2 diabetes.
Read More
DUBLIN – Sosei Group is paying £35 million (US$45.2 million) for a 25.6 percent stake in Mina Therapeutics Ltd. in a deal that gives it a commanding view of the emerging field of small activating RNA (saRNA) therapeutics.
Read More
PERTH, Australia – Although CEOs of life sciences companies in Australia said that 2016 was their strongest year yet, that optimism was dampened by uncertainty surrounding government policy on R&D tax incentives, according to AusBiotech's annual CEO survey.
Read More
